Abstract. Considering that the prognosis of patients with advanced biliary tract cancer (BTC) remains very poor, with a median survival of less than 1 year, new therapeutic approaches need to be developed. In the present study, a phase II clinical trial of personalized peptide vaccination (PPV) was conducted in advanced BTC patients to evaluate the feasibility of this treatment and to identify potential biomarkers. A maximum of 4 human leukocyte antigen-matched peptides, which were selected based on the pre-existing host immunity prior to vaccination, were subcutaneously administered (weekly for 6 consecutive weeks and bi-weekly thereafter) to 25 advanced BTC patients without severe adverse events. Humoral and/ orTcellresponsesspecifictothevaccineantigenswere substantially induced in a subset of the vaccinated patients. As shown by multivariate Cox regression analysis, lower interleukin-6 (IL-6) and higher albumin levels prior to vaccination and greater numbers of selected vaccine peptides were significantly favorable factors for overall survival [hazard ratio(HR)=1.123,95%confidenceinterval(CI)1.008-1.252, P= 0.035;HR= 0.158,95%CI0. P= 0.033;HR= 0.258,P= 0.006;respectively].Basedonthe safetyprofileandsubstantialimmuneresponsestovaccine antigens, PPV could be a promising approach for refractory BTC,althoughitsclinicalefficacyremainstobeinvestigated inlarger-scaleprospectivestudies.Theidentifiedbiomarkers are potentially useful for selecting BTC patients who would benefitfromPPV.
Introduction
Biliary tract cancer (BTC) is one of the most aggressive types of cancer and has a very poor prognosis (1, 2) . Only 10% of newly diagnosed patients present with early-stage disease, which may be treated by a potentially radical excision of the tumor, and the remaining patients have unresectable disease with locally advanced and/or metastatic tumors. Recently, there have been substantial advances in treatment modalities, including systemic chemotherapies, for advanced BTC (1) (2) (3) (4) . For example, a randomized trial has suggested that cisplatin plus gemcitabine could be considered as a standard treatment option for patients with advanced BTC (3) . In addition, a number of different targeted therapies for BTC have also been under investigation (1) (2) (3) (4) . Despite this progress, however, the prognosis of BTC patients remains very poor, with a median survival of less than 1 year. Therefore, further novel therapeutic approaches need to be developed.
We previously devised a new regime of peptide-based vaccination, known as 'personalized peptide vaccination (PPV)', in which vaccine antigens are selected and administered based on the pre-existing host immunity prior to vaccination (5-7). We reported favorable clinical and/or immune responses of this novel vaccination in various types of advanced cancer, including pancreatic, gastric, colorectal and prostate cancer, andglioblastoma (8) (9) (10) (11) (12) .Forexample,arecentlyconducted randomized clinical trial of PPV for advanced prostate cancer patients showed a promising clinical outcome in the vaccinated group (11) . In the present study, we addressed the feasibility of using PPV in advanced BTC patients in a small-scale phase II study. In addition, we identified potential biomarkers for predicting overall survival (OS) and selecting suitable patients for this treatment.
Patients and methods

Patients.
Patients were eligible for inclusion in the present study if they had a histological diagnosis of BTC and showed positive humoral responses to at least two of the 31 different vaccine candidate peptides (Table I) (13). Ifpeptide-specificIgGtiterstoatleastoneofthevaccine peptides in the post-vaccination plasma were more than 2-fold higher than those in the pre-vaccination plasma, the changes wereconsideredtobesignificant. Tcellresponsesspecifictothevaccinepeptideswere evaluated by interferon (IFN)-γ ELISPOT assay (MBL, Nagoya, Japan) using peripheral blood mononuclear cells (PBMCs). Briefly, PBMCs (2.5x10 4 cells/well) were incubatedin384-wellmicrocultureplates(Iwaki,Tokyo,Japan) with 25 µl of medium (OpTmizer™ T Cell Expansion SFM; Invitrogen, Carlsbad, CA, USA) containing 10% FBS (MP Biologicals, Solon, OH, USA), recombinant human interleukin (IL)-2 (20 IU/ml; Serotec, Oxford, UK) and 10 µM of each peptide. Half of the medium was removed and replaced with new medium containing a corresponding peptide (20 µM) after 3 days of culture. After incubation for the following 6 days, the cells were harvested and tested for their ability to produce IFN-γ in response to either the corresponding peptides or a negative control peptide from human immunodeficiency virus (HIV). Antigen-specific IFN-γsecretionafteran18-hincubationwasdeterminedby ELISPOT assay with the Zeiss ELISPOT reader (Carl Zeiss MicroImagingJapan,Tokyo,Japan).Antigen-specificTcell responses were evaluated by the difference between the spot numbers (mean of duplicate samples) in response to the corresponding peptides and those in response to the control peptide. The differences of at least 10 spot numbers per 10 5 PBMCswereconsideredsignificant.Ifthespotnumbersin response to at least one of the vaccine peptides in the postvaccination PBMCs were more than 2-fold higher than those in the pre-vaccination PBMCs, the changes were considered significant.
Measurement of C-reactive protein (CRP), serum amyloid A (SAA) and cytokines.
The levels of CRP, SAA and IL-6 in the plasma were examined by ELISA using kits from R&D Systems (Minneapolis, MN, USA), Invitrogen and eBioscience (San Diego, CA, USA), respectively. Bead-based multiplex assays were used to measure Th1/Th2 cytokines, including IL-2, IL-4, IL-5 and IFN-γ (Invitrogen) with the Luminex 200 system. Frozen plasma samples were thawed, diluted and assayed in duplicate in accordance with the manufacturer's instructions. The mean of duplicate samples was used for statistical analysis. Statistical methods. The two-sided Wilcoxon test was used to compare differences between pre-and post-vaccination measurements.OStimewascalculatedfromthefirstdayof peptide vaccination until the date of mortality or the last date when the patient was known to be alive. Predictive factors for OS were evaluated by univariate and multivariate analyses with the Cox proportional hazards regression model. P-values <0.05wereconsideredtoindicateastatisticallysignificant difference. All the statistical analyses were conducted using the SAS version 9.1 software (SAS Institute Inc., Cary, NC, USA).
Results
Patient characteristics. Between November 2008 and
December 2010, 25 BTC patients were enrolled in the present study. Table II shows the clinicopathological characteristicsoftheenrolledpatients.Therewere18maleand 7 female subjects, with a median age of 59 years, ranging from 37 to 79 years. Primary sites of BTC were 7 gallbladder carcinomas, 11 extrahepatic and 6 intrahepatic cholangiocarcinomas, and 1 periampullary carcinoma. All the patients had advanced-stage cancer (stage IVa, n=5; stage IVb, n=9; recurrent, n=11). Prior to enrollment, 22 patients failed to respond to 1 (n=13) or 2 (n=9) regimen(s) of chemotherapy, whereas the remaining 3 patients did not tolerate chemotherapy due to adverse events. The median duration of chemotherapy prior to the PPV was 4 months, ranging from 2 to 27 months. The performance status at the time of enrollment was grade 0 (n=20) or grade 1 (n=5). The numbers of peptides vaccinated tothepatientsatthefirstcycleofvaccinationwere4peptides in 19 patients, 3 in 5 patients and 2 in 1 patient. The median number of vaccinations was 10, with a range of 2 to 24. During the PPV, 20 of 25 patients were treated in combination with chemotherapy, but the remaining 5 patients did not tolerate combined chemotherapy (patients 2, 9, 12, 13 and 25).
Ofthe10vaccinatedpatientswhoseradiologicalfindings were available prior toandfollowingthefirstcycleofvaccination, none had a complete response (CR) or partial response (PR).Thebestresponsewasstabledisease(SD)in8(80%) patients. The remaining 2 patients (20%) had progressive disease (PD) ( Table II) .
Toxicities. The overall toxicities are shown in Table III . The most frequent adverse events were dermatological reactions at the injection sites (n=17), hematological toxicity (n=14) and cholangitis (n=11). Severe adverse events (grade 3) were as follows: injection site reaction (n=1), gastrointestinal hemorrhage (n=2), gastrointestinal stricture (n=1), cholangitis (n=11), anemia (n=1), hyperbilirubinemia (n=1) and elevation of ALT (n=1) and ALP (n=1). According to an assessment by the independent safety evaluation committee in this trial, all of these severe adverse events, except for 1 case with a grade 3 injection site reaction, were due to cancer progression or other causes, rather than to the vaccinations themselves.
Immune responses to the vaccine peptides. Both humoral and Tcellresponsesspecifictothevaccinepeptideswereanalyzed in blood samples prior to and following vaccination (data not shown). Plasma samples were obtained from 25, 20 and 8patientsbeforeandattheendofthefirst(6thvaccination) and second (12th vaccination) cycles of vaccination, respectively. The post-vaccination samples were not available in the patientswhofailedtocompletethefirstorsecondcycleof6 vaccinations due to disease progression. The IgG responses specifictoatleastoneofthevaccinepeptideswereaugmented in7of20patients(35%)andin7of8patients(88%)attheend ofthefirstandsecondcyclesofvaccination,respectively.
T cell responses to the vaccine peptides were measured by IFN-γ ELISPOT assay with PBMCs. PBMCs were available for this assay in 22, 17 and 7 patients prior to and at the end ofthefirstandsecondcycleofvaccination,respectively.In thepre-vaccinationsamples,antigen-specificTcell responses were detectable in 5 patients (23%). Of the 17 patients who completedthefirstcycleofvaccination,8patients(47%)showed an induction of T cell responses to the vaccine peptides. At theendofthesecondcycleofvaccination,theantigen-specific T cell responses were induced in 4 of 7 patients (57%). It should be noted that 3 of the 4 patients with positive T cell responses at the end of the second cycle of vaccination showed reactivity to more than 2 peptides. Collectively, substantial increasesinpeptide-specificIgGtitersand/orTcellresponses following vaccination were observed in a subset of the vaccinated patients.
Cytokines and inflammation markers. We then measured several cytokines, including IL-2, IL-4, IL-5, IL-6, IFN-γ and theinflammationmarkers,CRPandSSA,intheplasmaprior toandfollowingthefirstcycleofvaccination.IL-6wasdetect-ablein17of25patients(68%)priortovaccination(median, 2 pg/ml; range, 0-21). Among the 20 plasma samples availableattheendofthefirstcycleofvaccination,IL-6levels were increased, decreased or unchanged in 12, 5 or 3 patients, respectively (median 3 pg/ml; range 0-43). There was no significantdifferenceinthelevelsofIL-6between pre-and post-vaccination samples (P= 0.118, Wilcoxon test). Other cytokines, including IL-2, IL-4, IL-5 and IFN-γ, were rarely detectable in either pre-or post-vaccination plasma (data not shown).
Theinflammationmarker,CRP,wasdetectable inprevaccination plasma from all (100%) of the patients (median, 6.377 µg/ml; range, 0.043-8.891). Among the 20 plasma samplestestedattheendofthefirstcycleofvaccination,plasma CRPlevelswereincreasedordecreasedin12or8patients, respectively (median, 6.232 µg/ml; range, 1.331-17.332). Another inflammation marker, SAA, was also detected in pre-vaccinationplasmafrom21(84%)of25patients(median, 113.486µg/ml;range,0-134.425).Attheendofthefirstcycle of vaccination, plasma SAA levels were increased, decreased or unchanged in 12, 7 or 1 patients, respectively (median, 104.861µg/ml;range,0-138.917).Therewerenosignificant differences in the levels of CRP and SAA between pre-and post-vaccination samples (P=0.290 and P=0.252, respectively, Wilcoxon test).
Relationship between pre-vaccination clinical findings or laboratory data and OS.
To identify potential biomarkers useful for selecting suitable patients for PPV, a Cox proportional hazards regressionmodelwasusedwithpre-vaccinationclinicalfindings or laboratory data (Table IV) . In the univariate analysis, IL-6, CRP, albumin, SAA and hemoglobin in pre-vaccination samples(P=0.002,P=0.004,P=0.008,P=0.031andP=0.039, respectively), and the numbers of peptides selected for vaccination (P=0.039) were prognostic factors of OS. None of the other factors examined, such as age, gender, duration of previous chemotherapy, lymphocyte counts or frequencies of suppressive immune cell subsets (Treg and MDSCs) prior to vaccination, were statistically correlated with OS. Furthermore, multivariate Coxregressionanalysiswasperformedtodefinetheclinical and laboratory features that were independently associated with OS by adjusting for possible confounding factors. Only the factors with a prognostic association in the univariate analysis, including IL-6, CRP, albumin, hemoglobin and the numbers of peptides selected for vaccination, were used for the multivariate analysis. SAA was not included for this analysis, since the levels of SAA were highly correlated with those of CRP(Pearson'scorrelationco-efficient0.707;P= 0.0002).As shown in Table IV, 
Relationship between post-vaccination clinical findings or laboratory data and OS.
To further identify potential post-vaccination markers for predicting patient prognosis, the univariate and multivariate Cox analyses were also carried out withpost-vaccinationclinicalfindingsorlaboratorydatafrom thepatientswhocompletedthefirstcycleof6vaccinations (n=20). In the univariate analysis, levels of albumin, IL-6, CRP and hemoglobin (P=0.003, P=0.005, P=0.027 and P=0.031, respectively) and the number of vaccine peptides (P=0.033) were prognostic of OS. In addition, although not statisticallysignificant,positivehumoralresponsestothevaccine peptideshadatendencytobeassociatedwithOS(P= 0.089) and were also used for the multivariate Cox analysis. The multivariate analysis demonstrated that, among these factors with a potentially prognostic association in the univariate analysis, lower IL-6 levels and greater numbers of vaccine (Table V) . However, the other postvaccinationfactorswerenotsignificantlyassociatedwithOS.
Discussion
For patients with advanced or recurrent BTC that are ineligible for surgery, various regimens of chemotherapeutic agents have been investigated (1) (2) (3) (4) were substantially induced in a subset of the vaccinated patients. Toxicity of PPV mainly involved skin reactions at the injection sites, and no severe adverse events were observed. Based on the positive immune responses to vaccine antigens and the safety profile,PPVcouldbefurtherinvestigatedasoneofthepromising approaches for refractory BTC.
The most unique aspect of PPV is the 'personalized' selection of antigen peptides ideal for individual patients in consideration of the pre-existing host immunity prior to vaccination (5-7). In view of the heterogeneity and complexity of host immune responses against tumors, this approach appears to be more rational than vaccination with non-personalized 'universal' tumor antigens. Notably, in the present study, the numberofselectedandvaccinatedpeptideswassignificantly associated with OS in the multivariate analysis, suggesting that greater numbers of peptides would be required for better clinical responses, possibly due to the heterogeneity and complexity of host immune responses against tumors.
TableIV.Univariateandmultivariateanalyseswithpre-vaccinationclinicalfindingsandlaboratorydata.
Univariate analysis
Multivariate analysis
Hazard ratio (95% CI) P-value TableV.Univariateandmultivariateanalyseswithpost-vaccinationclinicalfindingsandlaboratorydata.
Univariate analysis Multivariate analysis
Hazard ratio (95% CI) P-value (5, (15) (16) (17) . At present, however, there is little information available regarding predictive biomarkers in patients undergoing cancer vaccines. In this study, the multivariate analysis demonstrated that lower IL-6 and higher albumin values, which may reflect less inflammation and betternutritionalstatus,priortovaccinationweresignificantly favorable factors for OS. IL-6 is a multifunctional cytokine that regulates various aspects of immune responses, acute phase reactions and hematopoiesis. In particular, IL-6 has been reported to be deeply involved in cancer development, such as tumorcellgrowthandcancer-associatedinflammation(18).
There have been a number of studies describing the correlation between IL-6 levels and prognosis in various types of cancer (19) (20) (21) (22) . IL-6 has also been reported to be one of the critical cytokines for inducing suppressive immune cell subsets. For example, MDSCs and Th17, which are known to modulate antitumor immunity, were shown to be generated from their precursors in the presence of IL-6 and other cytokines (23) (24) (25) . Although the role of IL-6 in the immune response to cancer vaccinesremainstobeclarified,itispossiblethattheblockage ofIL-6signalingwouldbebeneficialforenhancingthethera-peuticefficacyofcancervaccines.
In conclusion, the present study demonstrated that PPV induced substantial immune responses to vaccine antigens without severe adverse events in advanced BTC patients. In addition, the multivariate analysis suggested that lower plasma IL-6 and better nutritional status prior to vaccination and preexisting immune responses to greater numbers of antigens may contribute to better responses to PPV. Therefore, the evaluation of these factors prior to vaccination may be useful for selecting patientswhowouldbenefitfromPPVanddefiningeligibilityand/ or exclusion criteria for molecular-based personalized immunotherapy in BTC patients. Nevertheless, since this was a small study with a limited number of patients, all of whom received PPV,theclinicalefficacyofPPV,aswellastheclinicalutility oftheidentifiedfactorsinrefractoryBTCpatientsremaintobe confirmedinfuturelarger-scaleprospectivetrialsconductedin definedpatientpopulationswithorwithoutreceivingPPV.
